Currently in the Phase 1 trial for refractory lupus nephritis (LN, lupus-related kidney disease in which people do not respond to first-line immunosuppressive drugs or quickly relapse after remission), Kyverna’s investigational drug, KYV-101, was generally well tolerated by the first U.S. study participant with no signs of concern after 28-days of dosing.

KYV-101 is a CAR-T cell therapy designed to target B cells (immune system cells involved in the production of autoantibodies and lupus disease activity). This therapy targets a protein known as CD19, which is found on the surface of B cells. This particular protein plays a role in several malignancies and autoimmune diseases.

The open-label Phase 1 clinical trial continues to actively recruit study participants, targeting to enroll nine to 12 patients with LN across the US. Additionally, people with lupus are currently under treatment with KYV-101 in Europe for multiple indications.

Continue to follow the Lupus Foundation of America for KYV-101 developments, as well as other lupus drug development news. Learn more about medications used to treat lupus.

Read the announcement